ユビキチネーション経路はパーキンソン病の中心にあるのか?
Benoit I Giasson1, Virginia M-Y Lee
1Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Cell
|July 16, 2003
まとめ
パーキンソン病 (PD) は,特定の脳細胞の喪失を伴う. ユビキチン-プロテアソーム系を通じたタンパク質分解の障害は,この神経変性障害の発症の重要な要因である可能性があります.
科学分野:
- 神経変性疾患 神経変性疾患
- 分子生物学は分子生物学である.
- 神経学 神経学とは
背景:
- パーキンソン病 (PD) は,一般的な神経変性運動障害である.
- PDにおける運動欠陥は,黒い物質のドーパミナージックニューロンの喪失から生じる.
- このニューロンの損失を誘発する正確なメカニズムは,まだ完全に理解されていません.
研究 の 目的:
- パーキンソン病の病因学におけるタンパク質分解経路の役割を調査する.
- ユビキチン-プロテアゾーム系機能不全とパーキンソン病との関係を調査する.
主な方法:
- タンパク質の分解メカニズムに関する最近の研究のレビュー.
- プロテアソーム機能と神経変性との関係を示す証拠の分析.
- 神経細胞死に関与する生化学的経路の検討.
主要な成果:
- ユビキチン媒介型プロテアソーム機能の変異または減少は,いくつかの形態のパーキンソン病症に関連しています.
- 証拠は,PDの根本的な原因において,タンパク質の分解が重要な役割を果たすことを示唆しています.
結論:
- ユビキチン-プロテアソーム系は,パーキンソン病の病原性における重要な要因である.
- プロテアソームの機能に関するさらなる研究は,PDの新たな治療標的を明らかにする可能性がある.
さらに関連する動画
関連する概念動画
The Proteasome
7.8K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
7.8K
The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Parkinson Disease ll: Pathophysiology
26
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
26


